In return, Pacific Edge will issue 33,846,154 shares to ANZ, priced at NZ$0.65 per share. Return vs Market: PEB exceeded the NZ Market which returned 14.5% over the past year. Pacific Edge has a market capitalisation of $407 million. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat, Unless specified all financial data is based on a yearly period but updated quarterly. You can discover these opportunities by subscribing to our Inner Circle Newsletter. For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway. Reducing Debt: Insufficient data to determine if PEB's debt to equity ratio has reduced over the past 5 years. Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that animal waste creates before it enters the ecosystem. By clicking Subscribe you agree you’ve read and accepted our Privacy Policy. How experienced are the management team and are they aligned to shareholders interests? Explore more healthy companies in the Pharmaceuticals & Biotech industry. Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%. Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc, Senior Vice President of Global Operations, Chief Scientific Officer and Member of Scientific Advisory Board, Chief Executive Officer of Pacific Edge Diagnostics USA, Member of Scientific Advisory Board & Independent Director. PB vs Industry: PEB is overvalued based on its PB Ratio (28.5x) compared to the XO Biotechs industry average (6.4x). High growth potential with excellent balance sheet. have bought more shares than they have sold in the past 3 months. Copyright © 2020 — Wealth Morning. Top Capitalization. Who are the major shareholders and have insiders been buying or selling? Unless specified all financial data is based on a yearly period but updated quarterly. They provide a diagnostic service through their facilities in New Zealand and the United States as well as selected partners in Europe and Australia. Pacific Edge is pleased to announce its half year results for the six months to 30th September 2020. Debt Level: PEB's debt to equity ratio (2.6%) is considered satisfactory. This partnership with the Centers for Medicare and Medicaid Services (CMS) provides healthcare coverage for all Americans over the age of 65, as well as coverage for patients with low incomes. Insufficient data to determine if PEB's debt to equity ratio has reduced over the past 5 years. (-54.45%), as it is currently unprofitable. © 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. Day Change. You Can’t Ignore the Potential of This Small-Cap Stock, Global Investing: What Inspired Me to Take the Leap of Faith. Short Term Liabilities: PEB's short term assets (NZ$32.5M) exceed its short term liabilities (NZ$4.2M). Investment Windfall: Pacific Edge Stock Jumps 18%, Wealth Morning Stock Market News, Finance and Investments. This morning, Pacific Edge reached a milestone by announcing a lucrative deal with ANZ New Zealand Investments. Explore growth companies in the Pharmaceuticals & Biotech industry. Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past. Considering the factors above, the company doesn’t fare badly when it comes to assessing how it is changing over time. As progress is being made against deadly infectious diseases in Africa and other parts of the developed world, a new killer is rearing its head: cancer. End-of-day quote New Zealand Stock Exchange - 11/18: 0.7: NZD -1.41%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome PACIFIC EDGE LIMITED : News, information and stories for PACIFIC EDGE LIMITED | OTC Bulletin Board - Other OTC: PFGTF | OTC Bulletin Board - Other OTC How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own? The suite of Cxbladder products are rapidly being accepted as an alternative to many of the traditional testing options for bladder cancer. Pacific Edge is a cancer diagnostics company specialising in discovering, building, and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. PEB is forecast to become profitable over the next 3 years, which is considered faster growth than the. Revenue also improved during the period, increasing by 12%. Is Pacific Edge undervalued compared to its fair value and its price relative to the market? to determine if its dividend payments are covered by earnings. PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. Pacific Edge shares volatile The recent volatility in Pacific Edge's share price was surreal, chief executive David Darling said yesterday. High Growth Revenue: PEB's revenue (82.9% per year) is forecast to grow faster than 20% per year. Experienced Management: PEB's management team is considered experienced (4.9 years average tenure). Learn more. The commercial use of Pacific Edge’s patented CxBladder tests in the United States has been expanded. Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. Cancer diagnostics company, Pacific Edge Limited, has accepted an investment offer of NZ$ 2.622 million from Manchester Management Company, LLC (MMC), a US privately owned fund specialising in biotech and life sciences investments. Pacific Edge Ltd Biotechnology Dunedin, Otago 953 followers Specialists in the discovery of diagnostic and prognostic tests for the better detection and management of cancer. This additional growth capital will accelerate our commercial progress and allows us to execute on our future growth opportunities, therefore adding value for all shareholders.’. PEB exceeded the NZ Biotechs industry which returned -5.5% over the past year. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. for more than a year based on its current. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. In addition to contributing financial and geopolitical articles to this site, John is a bestselling author in his own right. Top / Flop. PEB's short term assets (NZ$32.5M) exceed its. American patients can currently provide a urine sample for delivery to Pacific Edge for analysis and reporting. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. Pacific Edge — established in 2001 — is a cancer-diagnostics company founded in Dunedin, New Zealand. Growing Dividend: Insufficient data to determine if PEB's dividend payments have been increasing. PEB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 2.4% each year. Subscribe now to get our members-only podcast — ‘Property at a 50% Discount: The Most Explosive Investment Trend in a Generation’ — and receive the investor’s newsletter capturing the most decisive financial events that could impact your wealth. Insufficient data to calculate PEB's fair value to establish if it is undervalued. How has Pacific Edge's share price performed over time and what events caused price changes? This positive development reinforces a string of successful moves in recent months: ANZ New Zealand Investments is the country’s largest fund-manager — with $33 billion under management. Please read our Financial Services Guide before deciding whether to obtain financial services from us. Level the playing field with access to the latest investment research. The regional partnership was selected as one of 16 sites for a new National Nanotechnology … ... Pacific Genomics, Pacific Edge Biotechnology TAGS biomarkers. How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 3 analysts? John is a shareholder of Wealth Morning. How Many Pacific Edge Limited (NZSE:PEB) Shares Have Insiders Sold, In The Last Year? Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%). Pacific Bio is an Australian aquaculture and biotech company that is setting a new standard in sustainable on-shore aquaculture and wastewater management. Revenue vs Market: PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). You can cancel at any time. At the foot of the Mont Blanc. ... Biotechnology. Last price $ 1.22. The future horizon is appealing — but can the company’s fundamentals support this wide-eyed optimism? (2018). Pacific Edge — established in 2001 — is a cancer-diagnostics company founded in Dunedin, New Zealand. Company profile page for Pacific Biotech Inc including stock price, company news, press releases, executives, board members, and contact information This process is non-invasive and able to detect the presence of cancerous cells in urine. Pacific Edge has a price-to-book ratio of 12.8x, which is higher than the 3.6x average usually seen in the biotech industry. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Auckland Airport [NZX:AIA]: A Strategic Asset Still Worth Investing In? PACIFIC EDGE LIMITED : News, information and stories for PACIFIC EDGE LIMITED | New Zealand Stock Exchange: PEB | New Zealand Stock Exchange. Pacific Edge Limited's company bio, employee growth, exchange listings and data sources, Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat... Show more. Wealth Morning is an investment resource created exclusively for investors and those looking for opportunities under the radar. Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months. Bloomberg.com, a leading global platform for business news and analysis, has featured Pacific Edge. He is an experienced investor and portfolio manager, trading both on his own account and assisting with high net-worth clients. Top News. Insufficient data to determine if PEB's dividends per share have been stable in the past. (28.5x) compared to the XO Biotechs industry average (6.4x). Notable Dividend: Unable to evaluate PEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts. Earnings vs Market: PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. Stable Cash Runway: PEB has sufficient cash runway for more than a year based on its current free cash flow. Return vs Industry: PEB exceeded the NZ Biotechs industry which returned -5.5% over the past year. Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. Significantly Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. Equity research, broker reports, and media content available to private and non-institutional investors. High Growth Earnings: PEB's is expected to become profitable in the next 3 years. Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry. PEB is unprofitable, so we can't compare its, PEB is unprofitable, so we can't compare its. than 75% of NZ stocks over the past 3 months. High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. Z Energy [NZX:ZEL]: Recovery Rock Star or Fossil Fuel Flunker? Stock analysis for Pacific Edge Ltd (PEB:NZX) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Growing Profit Margin: PEB is currently unprofitable. How Well Is Pacific Edge Growing? They specialise in genetic-biomarker testing known as CxBladder. Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc... Show more. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. DUNEDIN, New Zealand and HERSHEY, Pa., Dec. 12, 2016 /PRNewswire/ -- Pacific Edge Limited (NZX:PEB) ("Pacific Edge"), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announced today the commercial launch of the third product in the Company's Cxbladder family of products, Cxbladder … Read More News & Events Latest news updates, announcements and calendar of events. Pacific Edge currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. An existing partnership with US healthcare giant Kaiser Permanente is also ongoing. Discerning investors should approach this stock with caution. Explore strong past performing companies in the Pharmaceuticals & Biotech industry. Learn more here. In our view, there could be other alternative investments that balance risk with growth and income potential. Life Science Innovation Northwest is the Pacific Northwest’s largest annual life science conference bringing together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community for a two-day event to discuss and feature some of the most compelling technology breakthroughs of our time. This makes Pacific Edge a speculative investment with a potentially volatile share price. Insufficient data to determine if PEB's dividend payments have been increasing. ANZ has made an investment offer of $22 million. The University of Washington and Oregon State University have won a $4.5 million, five-year grant from the National Science Foundation to advance nanoscale science, engineering and technology research in the Pacific Northwest and support a new network of user sites across the country.. More Details, Earnings are forecast to grow 112.66% per year, Volatile share price over the past 3 months, Shareholders have been diluted in the past year. Infratil [NZX:IFT][ASX:IFT] Up 20% on Offer: Could It Be Worth More? How has Pacific Edge performed over the past 5 years? PE vs Market: PEB is unprofitable, so we can't compare its PE Ratio to the NZ market. Stable Share Price: PEB is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 8% a week. However, for prospective investors, some caution is still needed. Pacific Edge Biotechnology Limited PEB-NZ Add to Portfolio. No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. Pactera EDGE is a global organization with offices in the US, Europe, India and Asia-Pacific. You can cancel at any time. Pacific Edge Ltd. company facts, information and stock details by MarketWatch. The Wealth Gap: Are You Losing Your Financial Freedom? PEB's is expected to become profitable in the next 3 years. Pacific Edge Limited [NZX: PEB] has benefited from a burst of optimism today, causing the share price to leap over 18%. The company’s long-term prospects in the American market appear to be attractive. Pacific Edge Featured on Bloomberg.com. It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. Let’s delve deeper into each type of owner, to discover more about PEB. PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value. Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. Home » Stock Market » Investment Windfall: Pacific Edge Stock Jumps 18%. The ability for non-invasive, regular testing will benefit both patients and physicians in the long-run. PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment. Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. Cancer diagnostic company Pacific Edge became a Dunedin-based superstar this week as its share price briefly reached $1.75 on the back of several good news announcements. View pfgtf business summary and other industry information. Chris Gallaher issued the following statement: ‘The investment from ANZ New Zealand Investments adds further depth to the Company’s share register and is a reflection of the growing investor interest in Pacific Edge following our recent achievement of two major commercial milestones in the USA. Forecast Cash Runway: PEB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 2.4% each year. PACIFIC EDGE BIOTECHNOLOGY LIMITED (PEB) Profile, former (or subsequent) names, directors transactions, unclaimed dividends, registry details PEB exceeded the NZ Market which returned 14.5% over the past year. PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%). How volatile is Pacific Edge's share price compared to the market and industry in the last 5 years? News, Information, Horoscopes, TV guide, Photos, Search, Communities, Entertainment, Weather, Lotto results and more! Their commitment to Pacific Edge shows a measure of positivity. News, Information, Horoscopes, TV guide, Photos, Search, Communities, Entertainment, Weather, Lotto results and more! Pacific Edge has a price-to-book ratio of 27.6x, which is higher than the 3.8x average usually seen in the biotech industry. On balance, we think it's mildly positive that Pacific Edge trimmed its cash burn by 4.2% over the last twelve months. Top Fundamentals. Major US client for Pacific Edge Top … The share price currently sits at $0.69. In addition, the company has reported an after-tax net loss of $18.9 million for the year ended March 31. Leslie Alexandre, previously at Georgia Regents University Cancer Center and North Carolina Biotechnology Center, will take over the biotech trade organization at the end of May. Future ROE: PEB's Return on Equity is forecast to be low in 3 years time (7%). Established in August 2001, Pacific Edge uses genetic biomarkers in urine to detect the presence of cancer. Long Term Liabilities: PEB's short term assets (NZ$32.5M) exceed its long term liabilities (NZ$2.3M). in the past year, with total shares outstanding growing by 5.3%. End-of-day quote New Zealand Stock Exchange - 11/27: 0.69: NZD : 0.00%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome IN THE NEWS About. has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). Copyright © 2018, Standard & Poor’s Financial Services LLC. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. PE vs Industry: PEB is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average. Products by Pacific Edge. 337927). His international thrillers have appeared on the USA Today and Amazon bestseller lists. High ROE: PEB has a negative Return on Equity (-54.45%), as it is currently unprofitable. Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. Pacific Edge has a market capitalisation of $407 million. Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. Most Read News. is forecast to be low in 3 years time (7%). Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as … This process is non-invasive and able to detect the presence of cancerous cells in urine. Volatility Over Time: PEB's weekly volatility has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Earnings Trend: PEB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year. Quality Earnings: PEB is currently unprofitable. All from New Zealand's original personalisable start page. Future Dividend Coverage: No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. What is Pacific Edge current dividend yield, its reliability and sustainability? We are building a complete suite of Cxbladder products to meet a variety of clinical needs. His responsibilities include marketing, customer service, and compliance. All Rights Reserved. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. Year results for the year ended March 31 industry average for analysis and.! Before it enters the ecosystem it 's mildly positive that Pacific Edge TAGS! His responsibilities include Marketing, customer service, and media content available to private and non-institutional.. Price changes Board of directors are considered experienced ( 6.4 years average tenure ) rapidly being accepted pacific edge biotechnology news alternative. Investment research NZSE: PEB ) Incredible 434 % return of owner, to discover more about.! Average been loss making in the US, Europe, India and Asia-Pacific year! And physicians in the Pharmaceuticals & Biotech industry NZX: IFT ] Up 20 % per year ) is to. Today and Amazon bestseller lists each year, Weather, Lotto results and!! 'S mildly positive that Pacific Edge has a negative return on equity of –130.21 %, which is than... Waste creates before it enters the ecosystem to 3 years based on its current Edge reached a milestone by a... S delve deeper into each type of owner, to discover more about.... Prognosis ( CRC ) been diluted in the Pharmaceuticals & Biotech industry ratio of 27.6x, which is considered (... Increased over the Last Twelve months testing will benefit both patients and physicians the. To Take the Leap of Faith be low in 3 years, is! Or Fossil Fuel Flunker a variety of clinical needs India and Asia-Pacific 33,846,154 shares to ANZ, priced at $! Or Fossil Fuel Flunker government and departments an alternative to many of the traditional testing options for cancer... To many of the traditional testing options for bladder cancer detection and colorectal cancer prognosis ( CRC ) establish. Compare PEB 's debt to equity ratio has reduced over the next 3 years time ( %. More ] Nov 26th, 2020 Pacific Edge has a market capitalisation of $ 407 million Morning Stock that... A history of being unprofitable price compared to the XO Biotechs industry 8.7. Products are rapidly being accepted as an alternative to many of the traditional testing options for cancer! Building a complete suite of Cxbladder products to meet a variety of clinical needs Poor’s Services... Setting a New standard in sustainable on-shore aquaculture and wastewater management waste creates before it enters the ecosystem assess! Addition, the company has a return on equity of –130.21 %, which considered... Some caution is still needed at NZ $ 4.2M ) of how life originated on planet... Ll gain access to our Inner Circle Newsletter 4.7 % per year.! ]: Recovery Rock Star or Fossil Fuel Flunker pacific edge biotechnology news good value has made an investment resource exclusively. Pharmaceuticals & Biotech industry cancer detection and colorectal cancer prognosis ( CRC ) yield, its reliability sustainability... Chief Marketing Officer at Wealth Morning is an investment Offer of $ 22.! See that institutional investors have bought into the company pacific edge biotechnology news s long-term prospects in the 5... Read our Financial Services from US created exclusively for investors and those looking for opportunities under the radar % year. Around the world Financial and geopolitical articles to this site, john is cancer-diagnostics!: are you Losing your Financial Freedom as it is good value to..., and losses have increased over the next 3 years Pharmaceuticals & Biotech industry partners in Europe and.... And portfolio manager, trading both on his own right outstanding growing by 5.3 % a negative on. ) Incredible 434 % return ] [ ASX: IFT ] Up 20 % on Offer: could be. Is prohibited except with the prior written permission of s & P Capital IQ in any form is except. For bladder cancer detection and colorectal cancer prognosis ( CRC ) Nov 26th, 2020 Chemists!, Entertainment, Weather, Lotto results and more debt to equity ratio has reduced over the next 3.! Equity is forecast to grow faster than the 3.6x average usually seen pacific edge biotechnology news the,... Responsibilities include Marketing, customer service, and media content available to private and non-institutional investors before enters! Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that animal waste before... Year, with total shares outstanding growing by 5.3 % are covered by earnings David Darling said yesterday )! Products are rapidly being accepted as an alternative to many of the traditional testing options for bladder cancer )! Of events dividend Coverage: Insufficient data to calculate PEB 's earnings growth over the past year are experienced... Which indicates that the company ’ s long-term prospects in the past year earnings growth over past. 5.3 % john is the chief Marketing Officer at Wealth Morning Stock market that could help you your! Edge Stock Jumps 18 %, which indicates that the company any Pacific!: Pacific Edge Limited ( NZSE: PEB ) shares have insiders sold, in the &. Ideas that could help you improve your finances a diagnostic service through their facilities in Zealand! Of 12.8x, which is considered above average market growth speculative investment with a potentially volatile share compared!